FDA Approved: SINGULAIR — Supplemental Application (Organon LLC)

View source ↗

Summary

FDA approved Organon LLC's supplemental application for Singulair (montelukast sodium), granting approval of the requested supplemental action for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Exercise-induced Bronchoconstriction
• Seasonal Allergic Rhinitis

Drugs mentioned

• SINGULAIR (montelukast)

Snippet

SUPPL AP for SINGULAIR (MONTELUKAST SODIUM)